Overview
CytoSorbents Q3 2025 revenue rose 10% yr/yr to $9.5 mln, missing analyst expectations
Adjusted EPS for Q3 2025 beats analyst expectations
Company implements workforce reduction to accelerate cash-flow breakeven to Q1 2026
Outlook
CytoSorbents expects cash-flow breakeven by Q1 2026
Company anticipates FDA decision on DrugSorb-ATR by mid-2026
Result Drivers
DISTRIBUTOR SALES - Record sales in distributor territories and strong direct sales outside Germany drove revenue growth
COST REDUCTION - Workforce and cost reduction program implemented to accelerate cash-flow breakeven to Q1 2026
CREDIT AGREEMENT - Amended credit agreement with Avenue Capital Group strengthens balance sheet with $2.5 mln additional cash
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $9.49 mln | $10 mln (3 Analysts) |
Q3 Adjusted EPS | Beat | -$0.04 | -$0.05 (3 Analysts) |
Q3 EPS | -$0.05 | ||
Q3 Product Gross Margin | 70.00% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cytosorbents Corp is $4.00, about 84% above its November 12 closing price of $0.64
Press Release: ID:nPn8rmcgKa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)